Influence in the quality of life of the respiratory patients by environmental control and the acaricide Frontac®.

The present prospective, open, observational study assessed the effect of the use of standard environmental control measures together with the application of an acaricide-containing aerosol of esbiol/benzyl benzoate/piperonyl butoxide/2-phenylphenol (Frontac) on several clinical and environmental parameters in patients suffering from perennial allergic rhinoconjunctivitis related to house dust mites (HDM). Fifty-five patients were enrolled and studied for one year. Both symptoms and the patients' quality of life (evaluated by the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)) were assessed at several clinic visits. The amount of HDM antigen was semi-quantitatively estimated using the guanine test. We found a significant decrease (p < 0.001) in most nasal symptoms scores: sneezing, runny nose, stuffy nose and itching. The overall quality of life (QoL) score also showed a significant improvement during the study period; the mean score decrease found was 0.86 (CI 95 %, 0.54-1.17) (p < 0.001). Five of the seven domains included in the questionnaire decreased significantly: non-hayfever symptoms; practical problems; nasal symptoms; eye symptoms, and emotions. These QoL score decreases were found during the first 3 months and later remained stable at lower levels than at baseline. The content of guanine in dust samples decreased significantly from 2.17 0.75 to 1.43 0.68 (p < 0.001). No toxic adverse events were recorded. In conclusion, these results show an improvement in the quality of life and a clinical benefit of the long-term use of the new chemical acaricide tested, together with environmental measures, in the home of patients suffering from allergic respiratory pathology.

Influence in the quality of life of the respiratory patients by environmental control and the acaricide Frontac®

The present prospective, open, observational study assessed the effect of the use of standard environmental control measures together with the application of an acaricide-containing aerosol of esbiol/benzyl benzoate/piperonyl butoxide/2-phenylphenol (Frontac®) on several clinical and environmental parameters in patients suffering from perennial allergic rhinoconjunctivitis related to house dust mites (HDM). Fifty-five patients were enrolled and studied for one year. Both symptoms and the patients' quality of life (evaluated by the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)) were assessed at several clinic visits. The amount of HDM antigen was semi-quantitatively estimated using the guanine test. We found a significant decrease (p < 0.001) in most nasal symptoms scores: sneezing, runny nose, stuffy nose and itching. The overall quality of life (QoL) score also showed a significant improvement during the study period; the mean score decrease found was 0.86 (CI 95 %, 0.54-1.17) (p < 0.001). Five of the seven domains included in the questionnaire decreased significantly: non-hayfever symptoms; practical problems; nasal symptoms; eye symptoms, and emotions. These QoL score decreases were found during the first 3 months and later remained stable at lower levels than at baseline. The content of guanine in dust samples decreased significantly from 2.17 ± 0.75 to 1.43 ± 0.68 (p < 0.001). No toxic adverse events were recorded. In conclusion, these results show an improvement in the quality of life and a clinical benefit of the long-term use of the new chemical acaricide tested, together with environmental measures, in the home of patients suffering from allergic respiratory pathology (AU)

El estudio se realizó de manera prospectiva, abierta y observacional para valorar el efecto de las normas habituales de control ambiental de forma conjunta con la aplicación de un acaricida en aerosol de esbiol/bencil benzoato/piperonil/butóxido/2-fenilfenol (Frontac®) en pacientes afectos de rinoconjuntivitis perenne relacionada con sensibilización a ácaros del polvo doméstico. Cincuenta y cinco pacientes fueron incluidos y estudiados durante un año. Se procedió a tabular la calidad de vida de los pacientes mediante el cuestionario de calidad de vida para pacientes con rinoconjuntivitis. Los niveles de ácaros domésticos fueron evaluados de forma semicuantitiva mediante el test de guanina. Encontramos un significativo descenso (p < 0,001) en la mayoría de los registros de los síntomas nasales: estornudos, rinorrea, prurito nasal y obstrucción nasal. El registro del cuestionario de la calidad de vida también constató una significativa mejoría durante dicho periodo, siendo el descenso de la media del registro del 0,86 (IC 95 %, 0,54-1,17) (p < 0,001). Cinco de los siete ítems incluidos en el registro disminuyeron significativamente (síntomas respiratorios, problemas sociales, síntomas nasales, síntomas conjuntivales y síntomas afectivos). El registro del cuestionario descendió durante los primeros tres meses y se mantuvo con posterioridad por debajo de los valores basales de forma estable. El contenido de guanina de las muestras del polvo del habitat de los pacientes disminuyó significativamente de 2,17 ± 0,75 a 1,43 ± 0,68 (p < 0,001). No se detectaron reacciones tóxicas adversas. En conclusión, estos resultados demuestran una mejoría de la calidad de vida y mejoría clínica utilizando a largo plazo la aplicación del nuevo acaricida testado de forma conjunta con la aplicación de medidas ambientales del habitat de los pacientes que sufren enfermedad respiratoria alérgica (AU)